{"id":936699,"date":"2026-02-12T17:27:41","date_gmt":"2026-02-12T22:27:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pacbio-announces-fourth-quarter-and-full-year-2025-financial-results\/"},"modified":"2026-02-12T17:27:41","modified_gmt":"2026-02-12T22:27:41","slug":"pacbio-announces-fourth-quarter-and-full-year-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pacbio-announces-fourth-quarter-and-full-year-2025-financial-results\/","title":{"rendered":"PacBio Announces Fourth Quarter and Full Year 2025 Financial Results"},"content":{"rendered":"
\n

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025.<\/p>\n

\n Fourth quarter and full year results:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n Q4 2025<\/strong>\n <\/td>\n\n Q4 2024<\/strong>\n <\/td>\n\n FY 2025<\/strong>\n <\/td>\n\n FY 2024<\/strong>\n <\/td>\n<\/tr>\n
Revenue (in millions)<\/em><\/td>\n$44.6<\/td>\n$39.2<\/td>\n$160.0<\/td>\n$154.0<\/td>\n<\/tr>\n
Consumable revenue (in millions)<\/em><\/td>\n$21.6<\/td>\n$18.8<\/td>\n$82.0<\/td>\n$70.3<\/td>\n<\/tr>\n
Instrument revenue (in millions)<\/em><\/td>\n$17.3<\/td>\n$15.3<\/td>\n$53.8<\/td>\n$65.8<\/td>\n<\/tr>\n
Service and other revenue (in millions)<\/em><\/td>\n$5.7<\/td>\n$5.1<\/td>\n$24.2<\/td>\n$17.9<\/td>\n<\/tr>\n
RevioTM<\/sup> system placements<\/td>\n21<\/td>\n23<\/td>\n61<\/td>\n97<\/td>\n<\/tr>\n
VegaTM<\/sup> system placements<\/td>\n42<\/td>\n7<\/td>\n140<\/td>\n7<\/td>\n<\/tr>\n
Annualized Revio pull-through per system<\/td>\n~$242,000<\/td>\n~$240,000<\/td>\n~$233,000<\/td>\n~$252,000<\/td>\n<\/tr>\n
Ending cash, cash equivalents, and investments
(in millions)<\/em><\/td>\n		$279.5<\/td>\n$389.9<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
Gross margin, operating expenses, net income (loss), and net income (loss) per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release.<\/p>\n

\n
\n Fourth Quarter 2025 Results<\/u>
\n <\/strong>\n <\/p>\n

GAAP gross profit for the fourth quarter of 2025 was $16.6 million compared to $10.1 million for the fourth quarter of 2024. Non-GAAP gross profit for the fourth quarter of 2025 was $17.8 million compared to $12.3 million in the fourth quarter of 2024 and a non-GAAP gross margin of 40% in the fourth quarter of 2025 compared to 31% for the fourth quarter of 2024.<\/p>\n

GAAP operating expenses totaled $57.8 million for the fourth quarter of 2025, compared to $163.1 million for the fourth quarter of 2024. Non-GAAP operating expenses totaled $56.2 million for the fourth quarter of 2025, compared to $68.6 million for the fourth quarter of 2024. GAAP and non-GAAP operating expenses for the fourth quarter of 2025 and the fourth quarter of 2024 included non-cash share-based compensation of $8.6 million and $14.8 million, respectively. GAAP net loss for the fourth quarter of 2025 was $40.4 million, compared to GAAP net income of $2.4 million for the fourth quarter of 2024. GAAP basic net loss per share for the fourth quarter of 2025 was $0.13 compared to GAAP basic net income per share of $0.01 for the fourth quarter of 2024. GAAP net income and GAAP basic net income per share for the quarter ended December 31, 2024 include a $154.4 million gain on debt restructuring in relation to our note exchange that closed on November 21, 2024.<\/p>\n

Non-GAAP net loss was $37.6 million for the fourth quarter of 2025, compared to $55.3 million for the fourth quarter of 2024. Non-GAAP basic net loss per share for the fourth quarter of 2025 was $0.12 compared to $0.20 for the fourth quarter of 2024.<\/p>\n

GAAP Operating expenses, net income, and basic net income per share for the quarter ended December 31, 2024 included the impact of non-cash impairment charges of approximately $91.3 million related to goodwill and in-process research and development.<\/p>\n

\n
\n Full Year 2025 Results<\/u>
\n <\/strong>\n <\/p>\n

GAAP gross profit for full year 2025 was $45.8 million compared to $37.3 million for 2024. Non-GAAP gross profit for 2025 was $64.2 million compared to $51.1 million in 2024 and a non-GAAP gross margin of 40% in 2025 compared to 33% for 2024.<\/p>\n

GAAP operating expenses totaled $599.6 million for full year 2025, compared to $511.6 million for 2024. Non-GAAP operating expenses totaled $229.9 million for 2025, compared to $289.2 million for 2024. GAAP and non-GAAP operating expenses for 2025 and 2024 included non-cash share-based compensation of $37.7 million and $65.3 million, respectively.<\/p>\n

GAAP net loss for full year 2025 was $546.4 million, compared to $309.9 million for 2024. GAAP basic net loss per share for full year 2025 was $1.82 compared to $1.13 for 2024. GAAP net income and GAAP basic net income per share for the year ended December 31, 2024 include a $154.4 million gain on debt restructuring in relation to our note exchange that closed on November 21, 2024.<\/p>\n

Non-GAAP net loss was $158.8 million for full year 2025, compared to $228.0 million for 2024. Non-GAAP basic net loss per share for full year 2025 was $0.53 compared to $0.83 for 2024.<\/p>\n

\n Recent Highlights <\/strong>\n <\/p>\n